
Website: www.patheon.com TORONTO, Feb. 16 /CNW/ - Patheon Inc. (TSX: PTI) today announced that based on a preliminary review of 2006 results for the first quarter ended January 31, 2006, it expects that the previously disclosed difficulties with Omnicef(R) production at its Carolina, Puerto Rico facility will impact earnings by approximately 6 cents per share in the first quarter, not 3 cents per share as anticipated when the Company reported 2005 year end results in December 2005. The Company also reports that, in addition to the effect of normal seasonality and holiday production shutdowns in the first quarter, net earnings will be further reduced by other developments, including delays in production volumes at certain sites in both Europe and North America, and lower revenues from pharmaceutical development services projects, primarily in North America, caused, in part, by capacity constraints. The Company expects to report a loss of approximately 7 cents per share in the first quarter, before one-time charges relating to the refinancing completed in December 2005. At Carolina, initiatives to improve production line speeds are resulting in improved yields, and a third production line was validated earlier this month. These two initiatives are expected to result in higher production levels for the balance of the year. The delays and production constraints experienced at certain other of Patheon's manufacturing sites are expected to be resolved over the next three quarters of the year. Management, however, cautions that net earnings for the full year, before one-time items, may be lower than those of a year ago. Patheon will report detailed 2006 first quarter results on Friday, March 3, 2006 at approximately 7:00 a.m. (Eastern Standard Time). A webcast conference call with financial analysts will be held on Friday, March 3, 2006 at 10:00 a.m. (Eastern Standard Time). Interested parties are invited to access the live call, via telephone, in listen-only mode, at (416) 644-3426 (Toronto and International) or toll free at (800) 814-4862 (U.S., including Puerto Rico). Listeners are encouraged to dial in five to 15 minutes in advance to avoid delays. A live audio webcast, with a slide presentation, will also be available via the web at www.patheon.com. A telephone replay of the conference call will be available between March 3, 2006 and March 17, 2006 by calling (416) 640-1917 or (877) 289-8525 (toll free) and entering identification number 21175495, followed by the "No." key. The webcast will also be archived on www.patheon.com for three months. About Patheon Patheon (TSX:PTI; www.patheon.com) is a leading global provider of drug development and manufacturing services to the international pharmaceutical industry. Patheon operates a network of 14 facilities in the United States, Canada and Europe, employing more than 5,900 people and serving a client base of 200 pharmaceutical and biotechnology companies. Forward-Looking Statement This news release contains forward-looking statements with respect to Patheon, including its business operations and strategy and financial performance and condition. Although management believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties. Actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from expectations include, but are not limited to, currency fluctuations, the level of outsourcing services required by the pharmaceutical companies (and in particular our clients), the impact of changes in pharmaceutical development and manufacturing regulations and general economic and market factors (including inflation and changes in laws) and other factors discussed in materials filed with applicable securities regulatory authorities from time to time. %SEDAR: 00001700E